DPP4 and heart failure: However, a meta-analysis suggested that saxagliptin may be associated with an increased risk of heart failure-related hospitalizations (132), while another analysis found an increased risk of atrial fibrillation (RR = 1.52) associated with DPP-4 inhibitors (129).